TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

State-level Storage Equipment and Technology
U-NEURON BIOMEDICAL is devoted to the development of stem cell isolation, storage and clinical applications. It owns the Patent on the Technology of Isolation and Culture of Amniotic Fluid Stem Cell, and has signed a service contract on the support of cell operation laboratory facilities and instruments with Bioresource Collection and Research Center; meanwhile, it has completed the pre-clinical trial for treatment of urinary incontinence with amniotic fluid stem cells with National Yang-Ming University. Recently, U-NEURON BIOMEDICAL has cooperated with Linkou Chang Gung Memorial Hospital on clinical trials of a rare disease – osteogenesis imperfecta (glass doll), and continues the research and development of the latest cell treatment and applications. Through continuous research, U-NEURON BIOMEDICAL carries out manufacturing that meets clinical specifications, creates new stem cell therapy technologies to fill current medical gaps, and popularizes stem cell technology and cell therapy products through professional technology development and medical research, creating real value of regenerative medicine and a better life for humankind.

ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immune activities in combination with anti-infection and anti-cancer vaccines. ImmunAdd has developed an efficient and sustainable manufacturing process for IA-05. With POC purpose, ImmunAdd will continue to expand our development to clinical-stage programs.

ORAL PEPTIDE
Summary of development timelines-product
MIRA/JER Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal study
ANY003 Novel TNFα Inhibitor: Lead optimization
ANYOOX Open for collaboration